November 2020 // Investment

Synendos Therapeutics (Synendos), a biopharmaceutical company developing a new class of small molecules aimed at restoring the natural functioning of the endocannabinoid system in the brain with the potential for treating a wide range of Central Nervous System (CNS) disorders, announced it has raised CHF 20 million in a Series A financing co-led by Kurma Partners and Sunstone Life Science Ventures and participation from BERNINA BioInvest, Schroder Adveq, High-Tech Gründerfonds, Lichtsteiner Foundation, Essential Investments, Zürcher Kantonalbank and private investors.


Download here below the full press release.

Synendos Series A financing 12 Nov 2020
Download • 159KB

Recent Posts

See All

October 2020 // Funding

Synendos and Prof. Jürg Gertsch received an Innosuisse Innovation Grant (total value of CHF 950’000).

August 2019 // Funding

Synendos received a co-fund from the European Union as part of the SME Instrument programme (EUR 50’000).

© 2019 Synendos Therapeutics, Inc. All Rights Reserved.

  • LinkedIn - cerchio grigio
  • Twitter - cerchio grigio